RTP Mobile Logo

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Non-Small Cell Lung Cancer

SABCS14

TARGET AUDIENCE
This activity is intended for medical oncologists, breast cancer surgeons and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed cancer in women, and in 2013 in the United States alone the disease culminated in an estimated 232,340 new cases and 39,620 estimated deaths. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Because of this, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.